News Releases


09 August 2022
Consolidated net revenue increased by 48% year-over-year to $23.1 million in Q2 2022 Israel net revenue increased by 212% year-over-year to $7.2 million in Q2 2022 Announced achievement of THCV equity milestone TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc.








09 August 2022
Consolidated net revenue increased by 48% year-over-year to $23.1 million in Q2 2022 Israel net revenue increased by 212% year-over-year to $7.2 million in Q2 2022 Announced achievement of THCV equity milestone TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc.
24 June 2022
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announces that at its Annual Meeting of Shareholders held on June 23, 2022 (the “Meeting”) shareholders voting in person or by proxy held in total 265,763,587 common shares of the
21 June 2022
TORONTO and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third
10 May 2022
TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and Chief Executive Office, will speak at two upcoming conferences: Canaccord
10 May 2022
Consolidated net revenue increased by 99% year-over-year to $25.0 million in Q1 2022 Israel net revenue increased by 263% year-over-year to $9.1 million in Q1 2022 Increased market share in Canada and Israel in Q1 2022 Mike Gorenstein returned as Chief Executive Officer TORONTO, May 10, 2022 (GLOBE
29 April 2022
TORONTO, April 29, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its 2022 Annual Meeting of Shareholders on Thursday, June 23, 2022, at 11:00 a.m. ET. Cronos Group will be conducting the meeting in a virtual-only format via live
21 March 2022
Kurt Schmidt, President and Chief Executive Officer, to Retire TORONTO, March 21, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that the Board of Directors has appointed Mike Gorenstein as
01 March 2022
Consolidated net revenue increased 59% in Full Year 2021 compared to Full Year 2020 Announces the planned exit of its Peace Naturals Campus in Stayner, Ontario  to streamline supply chain and improve profitability TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc.
18 February 2022
Completed Audit Committee evaluation and restated Q2 2021 unaudited interim financial statements Announces strategic realignment to support future growth strategies Consolidated net revenue increased 80% in the third quarter of 2021 compared to the third quarter of 2020 Launched Cronos Group's
11 February 2022
TORONTO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”).
28 January 2022
TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”).
14 January 2022
TORONTO, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”).